Vision-threatening uveitis of unknown origin

Article

What to investigate: aqueous, vitreous or both?

The main advantage of diagnostic vitrectomy is obviously a larger volume of sample which allows a more thorough analysis and multiple investigations in one sample. In addition, vitrectomy may improve visual acuity, but its drawback is its invasiveness, possibility of adverse effects and higher costs.

In contrast, aqueous analysis is a less invasive procedure and may yield results faster. However, an aqueous tap provides a restricted volume of the sample (usually around 100–200 microlitres) and, therefore, allows only a limited number of examinations.

Conversely, outside Europe, diagnostic vitrectomy is frequently being performed as a primary surgical diagnostic procedure, and the acquired material is being assessed by PCR and other various methods including microbial cultures, cytology, immunophenotyping by flow cytometry and other examinations, usually based on clinical manifestations of the patients.

GWC is a more elaborate diagnostic assay than PCR and is, therefore, not universally used. Obviously, the simultaneous analyses of vitreous sample provide the most valuable assessment and prevent the need for multiple diagnostic interventions, but may limit the volume of separate samples. The diagnostic value of vitrectomy varies widely, which is certainly caused by the number of examinations performed with a given sample and by the selection of patients. The selection based on a clinical suspicion of specific diagnosis increases the positive outcome of a diagnostic procedure.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Alexandra Miere, MD, PhD, Associate Professor of Ophthalmology, University Paris Est Créteil, France, speaks at EURETINA
Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.
© 2024 MJH Life Sciences

All rights reserved.